POR and Training Program on Multidrug-Resistant Organisms

POR 和多重耐药菌培训计划

• 批准号: 10301971
• 负责人: Cesar Augusto Arias
• 金额: $ 12.54万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-25 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10301971
• 关键词: Antibiotic Resistance; Antimicrobial Resistance; Area; Award; Bacteremia; Basic Science; Cefazolin; Cell membrane; Cessation of life; Clinical; Clinical Microbiology; Clinical Sciences; Collaborations; Communicable Diseases; Complex; Country; Critical Illness; Development; Diagnostic; Doctor of Pharmacy; Doctor of Philosophy; Enterococcus; Evolution; Fostering; Foundations; Funding; Future; Generations; Genomics; Goals; Grant; Immunocompromised Host; Infection; Infrastructure; Institution; Lead; Leadership; Machine Learning; Medical center; Mentors; Mentorship; Metagenomics; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Mission; Molecular; Molecular Epidemiology; Multiple Bacterial Drug Resistance; Names; Organism; Outcome; Patients; Phenotype; Physicians; Population; Positioning Attribute; Postdoctoral Fellow; Predisposition; Program Research Project Grants; Public Health; Publications; Research; Research Personnel; Research Training; Resistance; Resources; Scientist; Secure; Sepsis; Structure; System; Talents; Testing; Texas; Therapeutic; Training; Training Programs; Translational Research; Translations; United Nations; United States National Institutes of Health; Vancomycin resistant enterococcus; Vision; academic standard; antimicrobial peptide; base; career; career development; clinical epidemiology; clinical practice; clinically relevant; commensal microbes; feasibility testing; genomic epidemiology; gulf coast; host microbiota; infection management; insight; inter-institutional; microbial genomics; microbiome research; microbiota; multi-drug resistant pathogen; next generation; novel; novel therapeutic intervention; pathogen; patient oriented; patient oriented research; programs; public health priorities; public health relevance; rapid test; recruit; response; skills; strength training; tool; translational study

ABSTRACT Antimicrobial resistance (AMR) is one of the most pressing public health priorities. AMR is thought to be re- sponsible for more than 35,000 deaths in the US with a projection of 300 million deaths worldwide by 2050. My original K24 application sought to increase my ability to conduct patient oriented research (POR) on antibiotic resistance and mentor a new generation of clinicians scientists on different aspects of this important public health threat. With support from the K24 award, I was able to markedly increase my research portfolio, launch a microbial genomics mission and increase my mentoring activities. Thus, the overarching goal of this com- petitive K24 renewal is to fully transition to an established investigator by continuing and further strengthening my POR portfolio and mentoring abilities. I also aim to fortify my leadership skills to expand an ambitious re- search and training program, focused on AMR. Supported in part by my original K24 award, I founded the Cen- ter for Antimicrobial Resistance and Microbial Genomics (CARMiG) at UTHealth. The vision of CARMiG was to amalgamate the world-class expertise available in the Houston’s Texas Medical Center (TMC) to serve as a major platform for cutting edge research programs and integrate a training mission to the highest level. I also led the creation of the Gulf Coast Consortium on Antimicrobial Resistance (GCC-AMR), an inter-institutional hub for AMR researchers across the TMC to interact and foster collaborations. We developed a robust training program on AMR, recruiting and supporting the career of a diverse pool of trainees (MD, PhDs and PharmDs) at different stages of their careers. My trainees have secured 4 NIH K developments awards (2 with perfect scores), and equivalent independent grants. Furthermore, the number of trainee’s publications has markedly expanded (94 publications as firs/corresponding author). Our NIH grant portfolio also grew with more than $ 20 million brought in as PI of NIH grants in the last 5 years, including a recent P01 program ($11m). We were also able to secure the first post-doctoral inter-institutional T32 training program on AMR. Thus, the foundations of my initial K24 program put me in an ideal position to sustain and further strengthen my research and training objectives. In my original K24 program I focused on the clinical and genomic aspects of vancomycin-resistant enterococci (VRE) one of the most challenging organisms in clinical settings. Using the expertise acquired in VRE, my K24 renewal will support new areas of research, including the intersection of microbiome science and AMR, genomics and molecular epidemiology of Gram-negative pathogens and use of machine learning to es- tablish clinical/genomic correlates in patients infected with multidrug-resistant organisms (MDRO). The spe- cific aims are: i) strengthen my portfolio of POR related to AMR as the foundation for trainees to develop their careers, and ii) mentor talented young investigators in translational and POR focused on AMR. I plan to con- tinue my robust mentoring program that integrates the understanding of the molecular and genomic bases of resistance and their translation into clinical practice.

抽象的 抗菌素耐药性（AMR）是最紧迫的公共卫生优先事项之一。 AMR被认为是重新 造成美国 35,000 多人死亡，预计到 2050 年全球将有 3 亿人死亡。 最初的 K24 申请旨在提高我对抗生素进行以患者为导向的研究 (POR) 的能力 抵制并在这一重要公众的不同方面指导新一代临床医生科学家 健康威胁。在 K24 奖项的支持下，我能够显着增加我的研究组合，推出 微生物基因组学任务并增加我的指导活动。因此，本次合作的总体目标是 竞争性 K24 更新是通过继续和进一步加强，全面过渡到已建立的调查员 我的 POR 作品集和指导能力。我还旨在加强我的领导技能，以扩大雄心勃勃的重新 搜索和培训计划，重点关注抗菌素耐药性。在我最初的 K24 奖项的部分支持下，我创立了 Cen- UTHealth 的抗菌素耐药性和微生物基因组学 (CARMiG) 术语。 CARMiG 的愿景是 合并休斯顿德克萨斯医疗中心 (TMC) 的世界一流专业知识，作为 尖端研究项目的主要平台，并将培训任务整合到最高水平。我也 领导创建了墨西哥湾沿岸抗菌素耐药性联盟 (GCC-AMR)，这是一个机构间组织 TMC 内 AMR 研究人员互动和促进合作的中心。我们开发了强大的培训 AMR 计划，招募和支持多元化学员（医学博士、博士和药学博士）的职业生涯 在他们职业生涯的不同阶段。我的学员获得了 4 项 NIH K 发展奖（2 项完美 分数），以及同等的独立资助。此外，实习生发表的论文数量也显着增加。 扩大（作为第一/通讯作者发表 94 篇论文）。我们的 NIH 拨款组合也增长了 20 多美元 过去 5 年作为 NIH 资助的 PI 带来了 100 万美元，包括最近的 P01 计划（1100 万美元）。我们也曾 能够获得第一个AMR博士后机构间T32培训项目。因此，基础 我最初的 K24 课程使我处于一个理想的位置，可以维持并进一步加强我的研究和培训 目标。在我最初的 K24 项目中，我专注于万古霉素耐药性的临床和基因组方面 肠球菌 (VRE) 是临床环境中最具挑战性的微生物之一。利用在以下领域获得的专业知识 VRE，我的 K24 更新将支持新的研究领域，包括微生物组科学和 AMR、革兰氏阴性病原体的基因组学和分子流行病学以及利用机器学习来研究 建立了感染多重耐药微生物（MDRO）的患者的临床/基因组相关性。该规格 cific 的目标是： i) 加强我与 AMR 相关的 POR 组合，作为学员发展自己的能力的基础 职业生涯，以及 ii) 指导有才华的年轻研究人员从事 AMR 领域的转化和 POR。我计划继续 继续我强大的指导计划，该计划整合了对分子和基因组基础的理解 耐药性及其转化为临床实践。